Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

PHYTOHEALTH CORPORATION

Home Clinical Trial Sponsors and OrganizationsPHYTOHEALTH CORPORATION

PHYTOHEALTH CORPORATION

5F, 167, Fuxing N. Rd., Taipei City, Taipei, Taiwan

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

18

0 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 2

12

66.7%

Phase 1

3

16.7%

Early Phase 1

1

5.6%

Phase 4

1

5.6%

Trial Status Distribution

Completed

13

72.2%

Recruiting

1

5.6%

Terminated

3

16.7%

Withdrawn

1

5.6%

Clinical Trials

Trials sponsored by this organization (18)

PG2 Injection for the Treatment of moderate-to Severe Fatigue in Breast Cancer Patients

May 202336 participants

PG2 Concurrent With Chemoradiation for Locally Advanced Esophageal Cancer

Feb 201948 participants

PG2 Breast Cancer Evaluation in Adjuvant Medicine Study

Mar 201867 participants

Study of PG2 Injection for Improving Fatigue in Patients After Palliative Abdominal Surgery for Cancer

Study of PHN131 in Patients After Surgery

Apr 2013106 participants

A Phase II Trial of PG2 in Patients With Advanced Pharyngeal or Laryngeal Squamous Cell Carcinoma Under Concurrent Chemoradiotherapy

Dec 201217 participants

PG2 Treatment for Improving Fatigue Among Advanced Cancer Patients Under Standard Palliative Care

Nov 2012323 participants

Study of PHN131 in Healthy Volunteers

Oct 201116 participants

Page 1 of 3

Approvals

No approval data available

News

PG2® Plus Chemoradiotherapy Improves Survival in Esophageal Cancer Patients

- A clinical study by PhytoHealth Corporation shows that Astragalus Polysaccharides (PG2®) combined with chemoradiotherapy (CCRT) significantly improves survival in advanced esophageal cancer patients. - Patients receiving PG2® with CCRT had longer overall survival and a higher tumor objective response rate compared to those receiving CCRT alone, indicating enhanced treatment efficacy. - PG2® modulates the tumor immune microenvironment (TIME), strengthens the immune system, and suppresses tumor growth, offering a new approach to esophageal cancer treatment. - The study suggests PG2® can help patients complete cancer treatment by reducing inflammation, improving strength, and mitigating cancer-related fatigue, leading to better therapeutic outcomes.

On this page

Overview
Clinical Trials18
Approvals
News1

Back to Organizations